Antinociceptive effects of intrathecal endomorphin-1 and -2 in rats

Life Sciences

Volumn 65, Issue 24, 1999, Pages 2635-2641

  Horvath, Gyöngyi ^a,b   Szikszay, Margit ^b   Tömböly, Csaba ^c   Benedek, György ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Antinociception; Carrageenan; Endogenous opioid peptides; Endomorphin; Hyperalgesia; Opioid; Spinal administration

Indexed keywords

CARRAGEENAN; ENDOMORPHIN 1; ENDOMORPHIN 2; MU OPIATE RECEPTOR AGONIST; OPIATE PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HYPOALGESIA; INTRATHECAL DRUG ADMINISTRATION; MOTOR DYSFUNCTION; NONHUMAN; PAIN; RAT; TACHYPHYLAXIS;

EID: 0033527609     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00532-9     Document Type: Article

References (25)

1. T.L. Yaksh and T.A. Rudy, J.Pharmacol.Exp.Ther. 202 411-413 (1977).
2. J.E. Zadina, L. Hackler, L.-J. Ge and A.J. Kastin, Nature 386 499-502 (1997).
3. L.S. Stone, C.A. Fairbanks, T.M. Laughlin, H.O. Nguyen, T.M. Bushy, M.W. Wessendorf and G.L. Wilcox, NeuroReport 8 3131-3135 (1997).
4. H.H. Loh, H.-C. Liu, A. Cavalli, W. Yang, Y.-F. Chen and L.-N. Wei, Mol.Brain Res. 54 321-326 (1999).
5. I.E. Goldberg, G.C. Rossi, S.R. Letchworth, J.P. Mathis, J. Ryan-Moro, L. Leventhal, W. Su, D. Emmel, E.A. Bolan and G.W. Pasternak, J.Pharmacol.Exp.Ther. 286 1007-1013 (1999).
6. H.C. Champion, J.E. Zadina, A.J. Kastin, L. Hackler, L.-J. Ge and P.J. Kadowitz, Biochem.Biophys.Res.Commun. 235 567-570 (1997).
7. H.C. Champion, J.E. Zadina, A.J. Kastin and P.J. Kadowitz, Peptides 19 925-929 (1998).
8. H.C. Champion and P.J. Kadowitz, Am.J.Physiol. 274(5) H1690-H1697(1998).
9. R. Shane, S. Wilk and R.J. Bodnar, Brain Res. 815 278-286 (1999).
10. V. Chapman, A. Diaz and A.H. Dickenson, Br.J.Pharmacol. 122 1537-1539 (1997).
11. L.E. Robson, M.G.C. Gillan and H.W. Kosterlitz, Eur. J. Pharmacol. 112 65-71 (1985).
12. T.L. Yaksh and T.A. Rudy, Physiol.Behav. 17 1031-1036 (1976).
13. P.A.J. Janssen, C.J.E. Niemegeers and J.C.G. Dony, Arzneim Forsch./Drug Res. 13 502-507 (1963).
14. K. Hargreaves, R. Dubner, F. Brown, C. Flores and J. Joris, Pain 32 77-88 (1988).
15. T.L. Pierce, M.D. Grahek and M.W. Wessendorf, NeuroReport 9 385-389 (1998).
16. S. Martin-Schild, J.E. Zadina, A.A. Gerall, S. Vigh and A.J. Kastin, Peptides 18 1645-1649 (1999).
17. M. Scherff, S. Schulz, D. Wiborny and V. Höllt, NeuroReport 9 1031-1034 1998).
18. K. Hosohata and T.H. Burkey, Eur.J.Pharmacol. 346 111-114 (1998).
19. L.J. Sim, Q. Liu, S.R. Childers and D.E. Selley, J.Neurochem. 70 1567-1576 (1998).
20. M. Spetea, K. Monory, Cs. Tömböly, G. Tóth, E. Tzavara, S. Benyhe, J. Hanoune and A. Borsodi, Biochem.Biophys.Res.Commun. 250 720-725 (1999).
21. J.L.K. Hylden, D.A. Thomas, M.J. Iadarola, R.L. Nahin and R. Dubner, Eur.J.Pharmacol. 194 135-143 (1991).
22. G. Horvath, M. Kovacs, M.Szikszay and G. Benedek, Eur.J.Pharmacol. 253 61-66 (1994).
23. J.Donnerer, R. Schuligoi and C. Stein, Neuroscience 49 693-698 (1992).
24. K.Ren and M.A. Ruda, NeuroReport 7 2186-2190 (1996).
25. M. Spetea, F. Otvos, G. Toth, T.M. Nguyen, P.W. Schiller, Z. Vogel and A. Borsodi, Peptides 19 1091-1098 (1998).